Medicines That Harm the Liver: Paracetamol, Painkillers, Antibiotics, TB Drugs — and the Statin Myth
Most medicines do not harm most livers, but a handful do so often enough to matter: paracetamol taken above its daily ceiling, anti-inflammatory painkillers in cirrhosis, amoxicillin-clavulanate, anti-tuberculosis drugs, and unregulated herbal or bodybuilding supplements. Statins are not on that list — they are safe in most liver disease. In our Asian ACLF database, drugs triggered 10.5% of cases, and herbal products accounted for 71.7% of those.
— Dr Chetan Kalal, DM Hepatology, Gleneagles Hospital Mumbai
Key takeaways
- Paracetamol is the painkiller hepatologists prefer, even in cirrhosis — at a ceiling your doctor sets. The danger is stacking several branded products that each quietly contain it.
- Anti-inflammatory painkillers rarely injure the liver directly, but in cirrhosis they can shut down the kidneys and provoke bleeding. EASL and AASLD both say avoid them once ascites appears.
- Amoxicillin-clavulanate is the commonest single cause of drug-induced liver injury in the US registry; jaundice typically appears about a month in, often after the course has ended.
- Anti-TB drugs remain India’s most important medicine-related liver threat. Three-quarters of injuries occur within two months — and TB tablets must never be stopped without the treating doctor.
- Statins do not damage the liver in any meaningful way. In cirrhosis, statin users had 46% lower decompensation and death in a meta-analysis of 121,058 patients.
- “Natural” is not “safe”. Herbal products were the commonest drug trigger of acute-on-chronic liver failure across Asia; bodybuilding powders laced with unlabelled anabolic steroids cause months of jaundice in young men.
A composite, not a real patient. A 52-year-old businessman from Dadar with fatty liver and diabetes arrives with a carry-bag of medicine strips. He has stopped his atorvastatin because a WhatsApp forward said statins “damage the liver”. He is taking a herbal liver tonic bought online, a protein-and-“testosterone booster” powder his gym recommended, and two different cold-and-fever tablets that both contain paracetamol. His ALT has doubled. The one medicine he abandoned was the one protecting him. The three he added are the ones I would have taken away.
That reversal — fearing the safe drug, trusting the dangerous one — is the commonest pattern I see in medicine-related liver trouble. My guide to drug-induced liver injury in India covers how hepatologists confirm a culprit drug, the TB data and the RUCAM scoring. This is the companion piece for the person at the chemist’s counter: which everyday medicines carry real liver risk, which are wrongly feared, and what changes once you already have a liver condition. One rule first. Nothing here is a reason to stop a prescribed medicine on your own; take the question — and the strip — to the doctor who prescribed it.
Paracetamol: safe within its ceiling, dangerous above it
Paracetamol is the painkiller I recommend most often to patients with liver disease. It is also the drug behind more acute liver failure in the West than any other. Both are true, and the whole distance between them is the dose.
Paracetamol toxicity, unlike most medicine-related liver injury, is dose-dependent rather than unpredictable. Below the daily ceiling on the packet, a healthy liver clears it without complaint. Above it, a toxic by-product accumulates faster than the liver can neutralise it, and cells die.
The US Acute Liver Failure Study Group followed 662 consecutive patients with acute liver failure; 275 (42%) were paracetamol cases, and nearly half of those were unintentional — people treating pain, not trying to harm themselves. Of that group, 38% had been taking two or more paracetamol-containing products at once. The Indian version is the cold-and-flu tablet, the fever syrup and the prescribed painkiller swallowed on the same day under three brand names, each listing paracetamol in small print. Read the composition line. If the word appears on more than one strip in your bag, you are stacking.
Patients with cirrhosis often avoid paracetamol altogether and reach for an anti-inflammatory instead. That is backwards. Reviews of pain management in cirrhosis — Chandok and Watt’s from the Mayo Clinic is the one most of us quote — conclude that paracetamol at a reduced daily limit is the safe option and the anti-inflammatories the dangerous one. Your hepatologist sets the ceiling, lower than the packet’s; regular alcohol lowers it further. I am not printing numbers because the right one depends on your liver, your weight and what else you take.
Anti-inflammatory painkillers: in cirrhosis the danger is the kidney
Ibuprofen, diclofenac, naproxen, aceclofenac, nimesulide, mefenamic acid — the NSAIDs — are sold over the counter everywhere in India and hide inside many “pain-and-fever” combination tablets. Direct liver injury from them is uncommon, though diclofenac does appear in the US registry’s series.
The real danger is indirect and specific to cirrhosis. A cirrhotic circulation keeps the kidneys perfused by leaning on prostaglandins; NSAIDs block them. What follows can be a sudden fall in kidney function, fluid retention that defeats the diuretics, a drop in sodium and — with platelets already low and varices possibly present — bleeding. One such episode can turn a stable patient into one with hepatorenal syndrome. The EASL 2018 guideline on decompensated cirrhosis and the AASLD 2021 ascites guidance say the same thing: avoid NSAIDs in cirrhosis with ascites.
If you have cirrhosis: no NSAID without your hepatologist’s knowledge — including the tablet for a toothache and the strip a relative hands you for back pain. If the composition names anything other than paracetamol, ask first.
Antibiotics and anti-TB drugs: the delayed jaundice
Antibiotics are the commonest class behind liver injury in Western registries, and one drug leads the table. In the US Drug-Induced Liver Injury Network, amoxicillin-clavulanate — the Augmentin family — was the most frequently implicated single agent: 117 of 1,038 cases, 11% of the registry. It favours older men. Symptoms appear a mean of 31 days after starting, often after the course is finished and forgotten. The injury is cholestatic — deep jaundice, itching — and slow: bilirubin took on average 55 days to settle from its peak. Three patients needed a transplant; none died.
Two more patterns from the same registry. Azithromycin was over-represented in people who already had liver disease. And when injury surfaced more than a year into treatment, the usual culprits were nitrofurantoin for recurrent urinary infection and minocycline for acne — both prescribed for months in India without a blood test.
Then tuberculosis. Anti-TB combination therapy is the medicine-related liver threat that matters most in this country; the DILI pillar post covers it in depth, so only the essentials here. Three of the four first-line drugs can injure the liver. In the Bangalore series of 269 patients with anti-TB liver injury, three-quarters of cases arose within the first two months and a quarter progressed to acute liver failure. The American Thoracic Society asks for liver-enzyme monitoring during treatment in anyone with a risk factor — alcohol use, existing liver disease, hepatitis B or C, HIV, pregnancy or the months after it. If that is you and nobody has checked your liver tests since you started, ask. And never stop TB tablets yourself; untreated tuberculosis kills more reliably than the drugs do. Yellow eyes, dark urine or vomiting on TB treatment mean a same-day review, not a self-imposed break.
The statin myth
No question comes up more often in my clinic, and no belief does more quiet damage. The fear has a kernel of truth: statins nudge ALT upwards in a minority, and early package inserts carried liver warnings. Serious statin liver injury is rare enough that most hepatologists see a handful of cases in a career.
The evidence is old and consistent. In 2004 Chalasani and colleagues compared 342 patients with raised liver enzymes who were started on a statin against 2,245 with similarly raised enzymes who were not. Severe enzyme elevations occurred in 0.6% and 0.4% respectively — no difference. A raised ALT at baseline did not make statins more dangerous.
It gets better than “not dangerous”. A 2017 meta-analysis of 13 studies and 121,058 patients with chronic liver disease found that among those with cirrhosis, statin users had 46% lower decompensation and 46% lower mortality, and the three randomised trials showed a 27% reduction in variceal bleeding or worsening portal hypertension. Moderate-quality evidence, and the authors asked for confirmatory trials — but the direction is unambiguous. The AASLD 2023 practice guidance says statins can be used safely in fatty liver disease, including compensated cirrhosis; decompensated cirrhosis is the one setting that needs a hepatologist’s judgement.
Remember what people with fatty liver actually die of: more often the heart than the liver. A patient with MASLD, diabetes and a high LDL who stops his statin because of a forward has traded a near-zero liver risk for a real cardiac one. If a doctor stopped yours for a mildly raised ALT, ask whether a hepatologist agrees. It is one of several beliefs I unpick in liver myths and facts.
Supplements, herbal products and gym powders
Here the reversal completes itself. The products patients trust most carry the least safety data, the least regulation, and the longest gap between swallowing and symptoms — so long that almost nobody connects the two.
During the pandemic, Giloy (Tinospora cordifolia) was promoted across India as an immunity booster. Hepatologists at 13 centres pooled what followed; I was one of the authors. Forty-three patients, more than half women, developed liver injury a median of 46 days after starting it. Many had autoimmune features on blood tests and biopsy, and the commonest presentation was not a fresh hepatitis but the unmasking of a chronic liver disease the patient had not known about. The herb had not caused their autoimmune hepatitis. It had set it alight.
The wider Asian picture is starker. In the APASL ACLF Research Consortium database of 3,132 patients with acute-on-chronic liver failure — a study I co-authored — drugs were the trigger in 329 (10.5%), and complementary and alternative medicines accounted for 71.7% of those, far ahead of anti-TB drugs at 27.3%. Ninety-day mortality in drug-induced ACLF was 46.5%, against 38.8% for other triggers.
Western registries tell the same story. In the US network, the share of liver injury attributed to herbal and dietary supplements rose from 7% to 20% between 2004 and 2013; non-bodybuilding products — weight-loss and “wellness” preparations, mostly in middle-aged women — ended in death or transplant in 13% of cases, against 3% for conventional medicines. Bodybuilding products behaved differently: 44 young men, median latency 73 days, every one jaundiced, 84% itching, jaundice lasting months. None died, but chemical analysis found anabolic steroids absent from the label. The gym powder is a pharmaceutical of unknown composition.
No bottle heals a liver. The things that help are unglamorous — I have written about what is actually worth drinking — and none carry “liver tonic” on the label. In clinic I ask about “powders, kadhas, capsules and tonics”, never just “medicines”, because patients do not file these under medicine. They should.
If you already have liver disease, the rules change
Everything above is more serious when the liver is already compromised. In the US network’s 899 confirmed cases, patients with pre-existing liver disease had a mortality of 16% against 5.2% in those without; the AARC figure of 46.5% is the Asian version of the same fact. Many of those patients did not know their liver was vulnerable until the drug found it out.
So if you have fatty liver, hepatitis B or C, alcohol-related liver disease or cirrhosis, three habits. Tell every prescriber — dentist, dermatologist, TB clinic — before they write anything. Keep one list of everything you swallow, supplements included. And know your baseline: a liver function test before a new long-term drug and a repeat a few weeks in catches a problem at the ALT stage rather than the yellow-eyes stage.
| Medicine or product | Liver risk | Who should be most careful | Sensible rule |
|---|---|---|---|
| Paracetamol | Low within the daily ceiling; serious and predictable above it. 42% of US acute liver failure cases. | Anyone taking several branded products; regular drinkers; cirrhosis (lower ceiling) | Read every composition line; one paracetamol product at a time; let your hepatologist set the limit in cirrhosis |
| NSAIDs (ibuprofen, diclofenac, naproxen, nimesulide, aceclofenac) | Direct liver injury uncommon; in cirrhosis the threat is kidney failure, fluid retention and bleeding | Cirrhosis, especially with ascites; anyone on diuretics | Avoid in cirrhosis unless a hepatologist says otherwise (EASL 2018, AASLD 2021) |
| Amoxicillin-clavulanate | Commonest single cause of DILI in the US registry (11%); cholestatic jaundice about a month in | Older men; repeated courses | Report jaundice or itching even weeks after the course ends |
| Long-course antibiotics (nitrofurantoin, minocycline) and azithromycin | Late injury after months of use; azithromycin over-represented in existing liver disease | Months-long prophylaxis or acne courses; existing liver disease | Ask for liver tests if a course runs beyond a few weeks |
| Anti-TB drugs | India’s leading medicine-related liver threat; a quarter of injuries reach liver failure | Alcohol use, existing liver disease, hepatitis B/C, HIV, pregnancy and post-partum | Monitoring if you have a risk factor; never stop without the treating doctor |
| Statins | Very low. Mild ALT rise in a few; serious injury rare. Linked to fewer complications in cirrhosis | Decompensated cirrhosis — a hepatologist decides | Do not stop for a mildly raised ALT; ask before any change |
| Herbal / Ayurvedic products (Giloy and many others) | Commonest drug trigger of ACLF across Asia (71.7% of drug cases); can unmask autoimmune hepatitis | Anyone with existing liver disease; women (autoimmune presentations) | Treat as a drug; declare it to every doctor; stop and get tested if unwell |
| Bodybuilding supplements | Prolonged cholestatic jaundice; unlabelled anabolic steroids | Young men | Assume the label is incomplete; avoid |
The signs that turn this into a same-day visit: yellowing of the eyes or skin, dark tea-coloured urine, persistent vomiting, unusual sleepiness or confusion, a swelling abdomen, or easy bruising while on any medicine or supplement. Bring everything you have been taking. In my Mumbai liver clinic the most useful object a patient can carry in is the bag of strips — the diagnosis is often inside it.
Frequently asked questions
Is paracetamol safe for the liver?
Yes, within the daily ceiling on the packet — and it is the painkiller hepatologists prefer, including in cirrhosis, where the doctor sets a lower limit. The danger is exceeding the ceiling, usually by taking several products that each contain paracetamol on the same day. Regular alcohol lowers the safe limit further.
Can I take painkillers if I have cirrhosis?
Paracetamol at a reduced limit set by your hepatologist is the standard choice. Anti-inflammatory drugs such as ibuprofen, diclofenac and naproxen should be avoided in cirrhosis, particularly once ascites has developed, because they can trigger kidney failure, fluid retention and bleeding. Never take an NSAID for cirrhosis-related pain without asking your liver doctor.
Do statins damage the liver?
No, not in any meaningful way. Serious statin liver injury is rare, and patients with raised liver enzymes are no more likely to develop it than anyone else. In cirrhosis, statin use has been linked to roughly 46% lower rates of decompensation and death. Do not stop a statin because of a mildly raised ALT; ask a hepatologist first.
Which antibiotics can affect the liver?
Amoxicillin-clavulanate is the commonest single cause of drug-induced liver injury in the US registry, typically producing jaundice and itching about a month after starting. Nitrofurantoin and minocycline can injure the liver after months of continuous use, and azithromycin has been over-represented in people with existing liver disease. Report jaundice even if the course has already finished.
Are Ayurvedic, herbal and bodybuilding supplements safe for the liver?
Not automatically. Herbal and alternative medicines were the commonest drug trigger of acute-on-chronic liver failure across Asia, Giloy has been linked to liver injury with autoimmune features in an Indian multicentre study, and bodybuilding powders have caused months of jaundice in young men, often because of anabolic steroids not listed on the label. Treat every supplement as a drug and tell your doctor about it.
Should I stop my TB medicines if my eyes turn yellow?
Not on your own. Yellow eyes, dark urine or vomiting on TB treatment need a same-day review by your doctor, who will check liver tests and decide which drugs to pause and how to reintroduce them. Stopping TB treatment unsupervised risks relapse and drug resistance; continuing blindly risks liver failure. Both decisions belong with your physician.
Book a consultation with Dr Chetan Kalal at Gleneagles Hospital, Mumbai — call +91 83294 76669 or use the appointment form on this site. International and NRI patients may request a teleconsultation.
References
- Devarbhavi H, Choudhury AK, Sharma MK, … Kalal C, … Sarin SK. Drug-induced acute-on-chronic liver failure in Asian patients. Am J Gastroenterol. 2019;114(6):929–937. PMID 31021832. doi:10.14309/ajg.0000000000000201
- Kulkarni AV, Hanchanale P, Prakash V, Kalal C, et al. Tinospora cordifolia (Giloy)-induced liver injury during the COVID-19 pandemic — multicenter nationwide study from India. Hepatol Commun. 2022;6(6):1289–1300. PMID 35037744. doi:10.1002/hep4.1904
- Larson AM, Polson J, Fontana RJ, et al. Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology. 2005;42(6):1364–1372. PMID 16317692. doi:10.1002/hep.20948
- Chandok N, Watt KD. Pain management in the cirrhotic patient: the clinical challenge. Mayo Clin Proc. 2010;85(5):451–458. PMID 20357277. doi:10.4065/mcp.2009.0534
- European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69(2):406–460. PMID 29653741. doi:10.1016/j.jhep.2018.03.024
- Biggins SW, Angeli P, Garcia-Tsao G, et al. Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2021;74(2):1014–1048. PMID 33942342. doi:10.1002/hep.31884
- Chalasani N, Bonkovsky HL, Fontana R, et al. Features and outcomes of 899 patients with drug-induced liver injury: the DILIN prospective study. Gastroenterology. 2015;148(7):1340–1352.e7. PMID 25754159. doi:10.1053/j.gastro.2015.03.006
- deLemos AS, Ghabril M, Rockey DC, et al. Amoxicillin-clavulanate-induced liver injury. Dig Dis Sci. 2016;61(8):2406–2416. PMID 27003146. doi:10.1007/s10620-016-4121-6
- Devarbhavi H, Singh R, Patil M, et al. Outcome and determinants of mortality in 269 patients with combination anti-tuberculosis drug-induced liver injury. J Gastroenterol Hepatol. 2013;28(1):161–167. PMID 23020522. doi:10.1111/j.1440-1746.2012.07279.x
- Saukkonen JJ, Cohn DL, Jasmer RM, et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med. 2006;174(8):935–952. PMID 17021358. doi:10.1164/rccm.200510-1666ST
- Chalasani N, Aljadhey H, Kesterson J, Murray MD, Hall SD. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology. 2004;126(5):1287–1292. PMID 15131789. doi:10.1053/j.gastro.2004.02.015
- Kim RG, Loomba R, Prokop LJ, Singh S. Statin use and risk of cirrhosis and related complications in patients with chronic liver diseases: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2017;15(10):1521–1530.e8. PMID 28479502. doi:10.1016/j.cgh.2017.04.039
- Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797–1835. PMID 36727674. doi:10.1097/HEP.0000000000000323
- Navarro VJ, Barnhart H, Bonkovsky HL, et al. Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network. Hepatology. 2014;60(4):1399–1408. PMID 25043597. doi:10.1002/hep.27317
- Stolz A, Navarro V, Hayashi PH, et al. Severe and protracted cholestasis in 44 young men taking bodybuilding supplements: assessment of genetic, clinical and chemical risk factors. Aliment Pharmacol Ther. 2019;49(9):1195–1204. PMID 30934130. doi:10.1111/apt.15211
- Chalasani NP, Maddur H, Russo MW, Wong RJ, Reddy KR. ACG Clinical Guideline: diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol. 2021;116(5):878–898. PMID 33929376. doi:10.14309/ajg.0000000000001259
- European Association for the Study of the Liver. EASL Clinical Practice Guidelines: drug-induced liver injury. J Hepatol. 2019;70(6):1222–1261. PMID 30926241. doi:10.1016/j.jhep.2019.02.014
- Devarbhavi H, Aithal G, Treeprasertsuk S, et al. Drug-induced liver injury: Asia Pacific Association of Study of Liver consensus guidelines. Hepatol Int. 2021;15(2):258–282. PMID 33641080. doi:10.1007/s12072-021-10144-3
